Solvonis secures exclusive CNS collaboration

AI SummaryClose X

Solvonis Therapeutics announced amendments to its consultancy agreement with CSO Professor David Nutt, who will now work exclusively with the company on CNS drug discovery and development and serve as Interim Chair of a newly established Scientific Advisory Committee. Additionally, Solvonis has agreed to settle £286,681 in outstanding liabilities by issuing 141,875,231 new ordinary shares. This includes 81,732,308 shares at £0.0013 each and 60,142,923 shares at £0.003 each. Application has been made for these shares to be admitted to trading on the Main Market of the London Stock Exchange around September 3rd, bringing the total issued share capital to 6,403,979,255 ordinary shares.

Disclaimer*

UK 100

Latest directors dealings